The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years,

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at risk from RSV disease,” the company’s chief scientific officer, Tony Wood, Ph.D., said in a release. “They also provide valuable insights into the potential impact of a second dose for certain populations.”

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people eligible for vaccination with the shot.

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease.

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,